GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PhoenixBio Co Ltd (TSE:6190) » Definitions » Altman Z-Score

PhoenixBio Co (TSE:6190) Altman Z-Score : 2.00 (As of May. 06, 2024)


View and export this data going back to 2016. Start your Free Trial

What is PhoenixBio Co Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Warning Sign:

Altman Z-score of 2 is in the grey area. This implies that the company is under some kind of financial stress. If it is below 1.8, the company may face bankruptcy risk.

PhoenixBio Co has a Altman Z-Score of 2.00, indicating it is in Grey Zones. This implies that PhoenixBio Co is in some kind of financial stress. If it is below 1.81, the company may face bankrupcy risk.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for PhoenixBio Co's Altman Z-Score or its related term are showing as below:

TSE:6190' s Altman Z-Score Range Over the Past 10 Years
Min: -0.02   Med: 1.87   Max: 11.46
Current: 2

During the past 9 years, PhoenixBio Co's highest Altman Z-Score was 11.46. The lowest was -0.02. And the median was 1.87.


PhoenixBio Co Altman Z-Score Historical Data

The historical data trend for PhoenixBio Co's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PhoenixBio Co Altman Z-Score Chart

PhoenixBio Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Altman Z-Score
Get a 7-Day Free Trial Premium Member Only 3.28 0.55 0.63 0.18 1.81

PhoenixBio Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.59 1.81 1.75 1.37 1.96

Competitive Comparison of PhoenixBio Co's Altman Z-Score

For the Biotechnology subindustry, PhoenixBio Co's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PhoenixBio Co's Altman Z-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PhoenixBio Co's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where PhoenixBio Co's Altman Z-Score falls into.



PhoenixBio Co Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

PhoenixBio Co's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.6366+1.4*-0.5916+3.3*0.043+0.6*2.0887+1.0*0.6644
=2.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2023:
Total Assets was 円2,698 Mil.
Total Current Assets was 円2,120 Mil.
Total Current Liabilities was 円403 Mil.
Retained Earnings was 円-1,596 Mil.
Pre-Tax Income was -13.347 + 15.59 + 47.564 + 64.119 = 円114 Mil.
Interest Expense was -0.553 + -0.495 + -0.477 + -0.47 = 円-2 Mil.
Revenue was 446.874 + 442.594 + 439.163 + 463.759 = 円1,792 Mil.
Market Cap (Today) was 円1,929 Mil.
Total Liabilities was 円924 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(2120.361 - 402.827)/2697.847
=0.6366

X2=Retained Earnings/Total Assets
=-1596.049/2697.847
=-0.5916

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(113.926 - -1.995)/2697.847
=0.043

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=1929.454/923.775
=2.0887

X5=Revenue/Total Assets
=1792.39/2697.847
=0.6644

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

PhoenixBio Co has a Altman Z-Score of 2.00 indicating it is in Grey Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


PhoenixBio Co  (TSE:6190) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


PhoenixBio Co Altman Z-Score Related Terms

Thank you for viewing the detailed overview of PhoenixBio Co's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


PhoenixBio Co (TSE:6190) Business Description

Traded in Other Exchanges
N/A
Address
3-4-1, Kagamiyama, Hiroshima Prefecture, Higashi-Hiroshima, JPN, 739-0046
PhoenixBio Co Ltd conducts study services for drug discovery and early development. It provides outsourcing services for drug development. The Company uses PXB-Mouse to conduct the study. Its services include pharmacokinetics related test, safety test, hepatitis virus (HBV / HCV) related drug efficacy test.

PhoenixBio Co (TSE:6190) Headlines

No Headlines